Clinical efficacy of melittin in the treatment of cats infected with the feline immunodeficiency virus. / Wirksamkeit von Melittin bei der Behandlung von Katzen mit feliner Immunschwächevirusinfektion.

OBJECTIVE: The bee venom melittin shows an antiviral efficacy against the human immunodeficiency virus in cell culture. It was shown to be non-toxic for cats. Aim of this pilot study was to investigate the clinical efficacy and side-effects of melittin in cats naturally infected with feline immunodeficiency virus (FIV). MATERIAL AND METHODS: The study was performed as a prospective, placebo-controlled double-blinded trial. Twenty cats were included, of which 10 cats each were treated with either melittin (500 µg/kg body weight) or phosphate-buffered saline (placebo) subcutaneously twice per week. During the treatment period of 6 weeks, the cats' general health status, determined by the Karnofsky's score, and the severity of clinical signs (conjunctivitis and stomatitis) using a clinical scoring system were evaluated. Haematology, biochemistry profiles, lymphocyte subpopulations, CD4/CD8 ratio, and pterines (biopterine, 7-xanthopterine) as surrogate parameters were also compared. RESULTS: The general health status and the clinical scores for conjunctivitis and stomatitis improved in cats treated with melittin. A statistically significant improvement however could only be detected for conjunctivitis in cats treated with melittin compared to cats treated with placebo which was likely due to different scores between both groups at the beginning. No influence on the lymphocyte subpopulations, CD4/CD8 ratio, and pterine concentrations was observed. No side effects occurred in this study. CONCLUSION AND CLINICAL RELEVANCE: In the protocol used in the present study, no significant efficacy of melittin could be detected. However, efficacy of melittin, especially if applied in a higher dosage as in the present study or for a longer period, could be evaluated in further studies. Synergistic effects if used in combination with classic antiretroviral drugs could be an interesting future approach.

Clinical efficacy of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine (PMPDAP) in the treatment of feline immunodeficiency virus-infected cats.

In in vitro studies, the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine (PMPDAP) inhibited the replication of feline immunodeficiency virus (FIV). No information about its clinical efficacy is available so far. The aim of this prospective placebo-controlled, double-blinded study was to evaluate the antiviral efficacy of PMPDAP in cats naturally infected with FIV. Twenty cats were randomly assigned to two treatment groups receiving either PMPDAP (25 mg/kg) or placebo twice per week subcutaneously for 6 weeks. The general health status (Karnofsky's score), clinical signs, laboratory, immunological, and surrogate parameters were evaluated. No significant differences were found between PMPDAP- and placebo-treated cats, although cats treated with PMPDAP showed a tendency for improvement in their Karnofsky's score and clinical signs. Haematological side effects were noted in the PMPDAP-treated cats. Thus, PMPDAP may be an option in treating cats if it becomes available for veterinarians, but side effects have been monitored.

Detection of bacterial and viral organisms from the conjunctiva of cats with conjunctivitis and upper respiratory tract disease.

A variety of pathogens are involved in conjunctivitis in cats. In this study, the prevalence of feline herpesvirus (FHV), Chlamydophila felis, mycoplasmas, and aerobic bacteria on the conjunctival surface of cats with conjunctivitis and upper respiratory tract disease was investigated by polymerase chain reaction (PCR), immunofluorescent assay (IFA), and aerobic bacterial culture of ocular swabs. Forty-one cats were included of which 37 were found to be infected with an ocular organism. Single and multiple infections were present in 15 and 22 cats, respectively. FHV, mycoplasmas, and C felis were detected by PCR in 11 (27%), 20 (49%), and 23 (56%) cats, respectively. IFA detected 10 cats as positive for C felis. Mycoplasma felis, Mycoplasma canadense, Mycoplasma cynos, Mycoplasma gateae, Mycoplasma lipophilum, and Mycoplasma hyopharyngis were identified by genetic sequencing. The most common aerobic bacteria cultured included Staphylococcus species, Streptococcus species and Micrococcus species. The prevalence of mycoplasmas in cats with conjunctivitis was higher than previously reported, and four of the Mycoplasma species have not been described in cats so far.